One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Progenity, Inc. logo
Progenity, Inc. PROG

Progenity, Inc. Financial Statements 2020-2011 | PROG

Annual Financial Statements Progenity, Inc.

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

339 M - - - - - - - - -

Shares

49.3 M - - - - - - - - -

Net Income

-193 M -148 M -129 M - - - - - - -

Revenue

74.3 M 144 M 128 M - - - - - - -

EBITDA

-190 M -134 M -108 M - - - - - - -

Operating Expenses

176 M 184 M 150 M - - - - - - -

General and Administrative Expenses

75.4 M 61.3 M 51.2 M - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Progenity, Inc. PROG
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Progenity, Inc. plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
- - $ 5.18 B usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
EyePoint Pharmaceuticals EyePoint Pharmaceuticals
EYPT
$ 0.27 -8.55 % $ 19.8 K usaUSA
Bio-Path Holdings Bio-Path Holdings
BPTH
- - $ 100 K usaUSA
Cara Therapeutics Cara Therapeutics
CARA
- -3.03 % $ 260 M usaUSA
ChromaDex Corporation ChromaDex Corporation
CDXC
- -0.88 % $ 598 M usaUSA
Caladrius Biosciences Caladrius Biosciences
CLBS
- -16.75 % $ 25.8 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCC
- -5.98 % $ 34.1 M usaUSA
Diffusion Pharmaceuticals Diffusion Pharmaceuticals
DFFN
- 11.68 % $ 8.97 M usaUSA
Eloxx Pharmaceuticals Eloxx Pharmaceuticals
ELOX
- -5.68 % $ 8.28 M usaUSA
Enochian Biosciences Enochian Biosciences
ENOB
- - $ 40.5 M usaUSA
Esperion Therapeutics Esperion Therapeutics
ESPR
- - $ 661 M usaUSA
Evofem Biosciences Evofem Biosciences
EVFM
- 7.55 % $ 38.1 M usaUSA
Eyenovia Eyenovia
EYEN
- 49.81 % $ 13.2 M usaUSA
FibroGen FibroGen
FGEN
- - $ 889 M usaUSA
Homology Medicines Homology Medicines
FIXX
- 0.77 % $ 53.4 M usaUSA
Amicus Therapeutics Amicus Therapeutics
FOLD
- - $ 4.47 B usaUSA
Frequency Therapeutics Frequency Therapeutics
FREQ
- - $ 528 M usaUSA
Galecto Galecto
GLTO
- - $ 762 M danmarkDanmark
GlycoMimetics GlycoMimetics
GLYC
- 9357.83 % $ 1.01 B usaUSA
Graybug Vision Graybug Vision
GRAY
- -11.23 % $ 9.65 M usaUSA
Galera Therapeutics Galera Therapeutics
GRTX
- -32.59 % $ 7.61 M usaUSA
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
- 1.35 % $ 17.8 M chinaChina
Novavax Novavax
NVAX
$ 7.91 -0.69 % $ 1.28 B usaUSA
Hepion Pharmaceuticals Hepion Pharmaceuticals
HEPA
- -18.79 % $ 39.3 K usaUSA
Hoth Therapeutics Hoth Therapeutics
HOTH
- - $ 18.8 M usaUSA
IMARA IMARA
IMRA
- 15.96 % $ 663 M usaUSA
KalVista Pharmaceuticals KalVista Pharmaceuticals
KALV
- - $ 1.45 B britainBritain
KemPharm KemPharm
KMPH
- -0.34 % $ 200 M usaUSA
Kezar Life Sciences Kezar Life Sciences
KZR
- - $ 53.3 M usaUSA
Lixte Biotechnology Holdings Lixte Biotechnology Holdings
LIXT
- - $ 63.4 M usaUSA
Magenta Therapeutics Magenta Therapeutics
MGTA
- -7.74 % $ 41.6 M usaUSA
NovaBay Pharmaceuticals NovaBay Pharmaceuticals
NBY
- - $ 11.3 M usaUSA
NeuroBo Pharmaceuticals NeuroBo Pharmaceuticals
NRBO
- 0.43 % $ 12 M usaUSA
OncoCyte Corporation OncoCyte Corporation
OCX
- 17.22 % $ 355 K usaUSA
Onconova Therapeutics Onconova Therapeutics
ONTX
- -0.47 % $ 21 M usaUSA
Opthea Limited Opthea Limited
OPT
- - $ 1.2 B australiaAustralia
Verastem Verastem
VSTM
$ 6.87 -7.29 % $ 476 M usaUSA
BiomX BiomX
PHGE
$ 1.85 14.2 % $ 3.02 M israelIsrael
Pieris Pharmaceuticals Pieris Pharmaceuticals
PIRS
- -15.58 % $ 1.22 B germanyGermany
Plus Therapeutics Plus Therapeutics
PSTV
- - $ 301 M usaUSA
Pluristem Therapeutics Pluristem Therapeutics
PSTI
- -1.9 % $ 33.3 M israelIsrael
Qualigen Therapeutics Qualigen Therapeutics
QLGN
- 5.59 % $ 1.16 M usaUSA
Qilian International Holding Group Limited Qilian International Holding Group Limited
QLI
- -6.08 % $ 184 M chinaChina